logo image

BELZUTIFAN

BELZUTIFAN

Tablet

Belzutifan is an inhibitor of hypoxia-inducible factor-2α (HIF-2α). The chemical name of belzutifan is 3­ [[(1S,2S,3R)-2,3-Difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5­ fluorobenzonitrile. The molecular formula is C17H12F3NO4S and the molecular weight is 383.34 Daltons
Tablets: 40 mg, blue, oval shaped, film-coated, debossed with “177” on one side and plain on the other side
The recommended dosage of WELIREG is 120 mg administered orally once daily with or without food.
WELIREG is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Contact Us

Established in New Delhi, India in 2020, ImpoMed Healthcare has grown over the years from a new start up to one of the Most Preferred Company for Facilitation of the Imported Drugs-Only USFDA/European FDA Approved.

Quick Links

Diseases

Corporate Office